Literature DB >> 21590474

[Therapeutic strategies in rheumatoid arthritis].

H Bastian1, E Feist, G-R Burmester.   

Abstract

Rheumatoid arthritis is the most common chronic inflammatory-rheumatic joint disease. If untreated, patients develop radiologically detectable progressive joint destruction. Rheumatoid arthritis has considerable socioeconomic importance, since a majority of patients are affected at employable age and can be significantly disabled over the course of the disease. Therefore, an appropriate early intervention with disease modifying anti-rheumatic drugs as well as ergo- and physiotherapy plays an important role for the prognosis. In the past few years, the introduction of novel drugs has improved the treatment opportunities markedly. This progress was the basis for new treatment strategies of tight disease control with the goal of disease remission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590474     DOI: 10.1007/s00108-010-2765-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  62 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints.

Authors:  M Backhaus; G R Burmester; D Sandrock; D Loreck; D Hess; A Scholz; S Blind; B Hamm; M Bollow
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 4.  Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome.

Authors:  Deborah P M Symmons
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

5.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

6.  Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging.

Authors:  M Backhaus; T Kamradt; D Sandrock; D Loreck; J Fritz; K J Wolf; H Raber; B Hamm; G R Burmester; M Bollow
Journal:  Arthritis Rheum       Date:  1999-06

7.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.

Authors:  G V Campion; M E Lebsack; J Lookabaugh; G Gordon; M Catalano
Journal:  Arthritis Rheum       Date:  1996-07

8.  The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography.

Authors:  R J Wakefield; W W Gibbon; P G Conaghan; P O'Connor; D McGonagle; C Pease; M J Green; D J Veale; J D Isaacs; P Emery
Journal:  Arthritis Rheum       Date:  2000-12

9.  Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints.

Authors:  Uffe Møller Døhn; Bo J Ejbjerg; Michel Court-Payen; Maria Hasselquist; Eva Narvestad; Marcin Szkudlarek; Jakob M Møller; Henrik S Thomsen; Mikkel Østergaard
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

View more
  1 in total

1.  [Biologicals 2012].

Authors:  M Gaubitz
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.